Deep Track Capital, LP — 13F Holdings & Portfolio
CIK 1856083 · latest 13F-HR filed 2026-08-14
Deep Track Capital, LP manages $6.87B in 13F-reported U.S. long-equity assets across 67 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are GH (7.41%), IMVT (5.24%), GPCR (3.70%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 18 new positions, exited 14, added to 32, and trimmed 10.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
3RD FLOOR
GREENWICH, CT 06830
$6.87B
Long-equity book
67
Distinct positions
2026-06-30
Filed 2026-08-14
+18 / −14 / ↑32 / ↓10
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- VERADERMICS INC$214.3M +678.7%
- GUARDANT HEALTH INC$200.7M +65.1%
- BIOMARIN PHARMACEUTICAL INC$124.3M +191.3%
- COMPASS PATHWAYS PLC$104.8M +155.9%
- NURIX THERAPEUTICS INC$89.3M +90.8%
Top Trims
- IMMUNOCORE HLDGS PLC-$48.4M -83.0%
- CYTOKINETICS INC-$30.9M -34.2%
- TARSUS PHARMACEUTICALS INC-$21.8M -8.6%
- CONTEXT THERAPEUTICS INC-$15.3M -78.9%
- AXSOME THERAPEUTICS INC.-$14.6M -7.8%
New Positions
- ALNYLAM PHARMACEUTICALS INC$248.3M
- HEMAB THERAPEUTICS HLDGS INC$132.3M
- GH RESEARCH PLC$89.6M
- UNITED THERAPEUTICS CORP DEL$67.0M
- AVALO THERAPEUTICS INC$66.7M
Exited Positions
- APELLIS PHARMACEUTICALS INC$182.3M
- CENTESSA PHARMACEUTICALS PLC$125.4M
- BRIDGEBIO PHARMA INC$62.5M
- TERNS PHARMACEUTICALS INC$56.6M
- GERON CORP$47.3M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | GUARDANT HEALTH INC | GH | 40131M109 | $509.1M | 7.41% | 3,393,312 | SH |
| 2 | IMMUNOVANT INC | IMVT | 45258J102 | $359.9M | 5.24% | 9,341,151 | SH |
| 3 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $254.4M | 3.70% | 4,740,072 | SH |
| 4 | VAXCYTE INC | PCVX | 92243G108 | $250.0M | 3.64% | 4,300,000 | SH |
| 5 | ALNYLAM PHARMACEUTICALS INC | ALNY | 02043Q107 | $248.3M | 3.61% | 825,000 | SH |
| 6 | VERADERMICS INC | MANE | 922967104 | $245.9M | 3.58% | 2,000,000 | SH |
| 7 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $230.8M | 3.36% | 3,666,768 | SH |
| 8 | NUVALENT INC | NUVL | 670703107 | $220.2M | 3.21% | 1,783,322 | SH |
| 9 | ALKERMES PLC | ALKS | G01767105 | $209.6M | 3.05% | 4,000,000 | SH |
| 10 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $193.3M | 2.81% | 19,686,282 | SH |
| 11 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $189.3M | 2.75% | 3,307,481 | SH |
| 12 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $187.7M | 2.73% | 7,736,455 | SH |
| 13 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $183.3M | 2.67% | 1,926,000 | SH |
| 14 | ALUMIS INC | ALMS | 022307102 | $178.6M | 2.60% | 6,348,558 | SH |
| 15 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $174.4M | 2.54% | 2,200,000 | SH |
| 16 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $172.1M | 2.50% | 12,161,496 | SH |
| 17 | VERA THERAPEUTICS INC | VERA | 92337R101 | $171.6M | 2.50% | 4,000,000 | SH |
| 18 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $171.3M | 2.49% | 700,000 | SH |
| 19 | GENMAB A/S | GMAB | 372303206 | $155.2M | 2.26% | 5,650,000 | SH |
| 20 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $136.3M | 1.98% | 6,999,025 | SH |
| 21 | HEMAB THERAPEUTICS HLDGS INC | COAG | 423494103 | $132.3M | 1.93% | 3,602,093 | SH |
| 22 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $131.3M | 1.91% | 4,200,000 | SH |
| 23 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $129.4M | 1.88% | 2,750,000 | SH |
| 24 | GRAIL INC | GRAL | 384747101 | $125.3M | 1.82% | 1,834,944 | SH |
| 25 | BICARA THERAPEUTICS INC | BCAX | 055477103 | $121.7M | 1.77% | 4,100,000 | SH |
| 26 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $111.4M | 1.62% | 3,732,569 | SH |
| 27 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $109.4M | 1.59% | 2,939,151 | SH |
| 28 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $108.8M | 1.58% | 3,352,804 | SH |
| 29 | MBX BIOSCIENCES INC | MBX | 55287L101 | $95.6M | 1.39% | 1,732,569 | SH |
| 30 | GH RESEARCH PLC | GHRS | G3855L106 | $89.6M | 1.30% | 3,333,334 | SH |
| 31 | GENMAB A/S Call | GMAB | 372303206 | $82.4M | 1.20% | 3,000,000 | SH |
| 32 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $77.4M | 1.13% | 2,000,000 | SH |
| 33 | ATAIBECKLEY INC | ATAI | 04650F101 | $76.0M | 1.11% | 14,417,442 | SH |
| 34 | UNITED THERAPEUTICS CORP DEL | UTHR | 91307C102 | $67.0M | 0.97% | 123,616 | SH |
| 35 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $66.7M | 0.97% | 3,610,000 | SH |
| 36 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $66.0M | 0.96% | 3,592,740 | SH |
| 37 | CYTOKINETICS INC | CYTK | 23282W605 | $59.6M | 0.87% | 700,000 | SH |
| 38 | ALTIMMUNE INC | ALT | 02155H200 | $58.5M | 0.85% | 19,250,000 | SH |
| 39 | PERSONALIS INC | PSNL | 71535D106 | $53.6M | 0.78% | 4,000,000 | SH |
| 40 | ACLARIS THERAPEUTICS INC | ACRS | 00461U105 | $49.4M | 0.72% | 9,345,000 | SH |
| 41 | CORMEDIX INC | CRMD | 21900C308 | $49.3M | 0.72% | 6,274,076 | SH |
| 42 | GENEDX HOLDINGS CORP | WGS | 81663L200 | $48.1M | 0.70% | 700,000 | SH |
| 43 | HARROW INC | HROW | 415858109 | $41.2M | 0.60% | 969,000 | SH |
| 44 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $37.2M | 0.54% | 2,491,939 | SH |
| 45 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $35.6M | 0.52% | 3,565,062 | SH |
| 46 | BEAM THERAPEUTICS INC | BEAM | 07373V105 | $34.3M | 0.50% | 1,000,000 | SH |
| 47 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $33.3M | 0.48% | 1,500,000 | SH |
| 48 | IMMIX BIOPHARMA INC | IMMX | 45258H106 | $28.6M | 0.42% | 2,775,000 | SH |
| 49 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $27.5M | 0.40% | 5,878,757 | SH |
| 50 | SHATTUCK LABS INC | STTK | 82024L103 | $25.7M | 0.37% | 3,706,734 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $6.87B | 67 | 0001856083-26-000004 |
| 2026-03-31 | 2026-05-15 | $6.12B | 63 | 0001856083-26-000003 |
| 2025-12-31 | 2026-02-13 | $5.61B | 55 | 0001856083-26-000001 |
| 2025-09-30 | 2025-11-14 | $3.58B | 56 | 0001856083-25-000006 |